Eli Lilly's Trading Volume Plummets 44.2% to 35th Position Amidst Obesity Drug Competition

On June 24, 2025, Eli Lilly (LLY) experienced a significant decline in trading volume, with a 44.2% decrease from the previous day, totaling 17.00 billion. This placed Eli Lilly at the 35th position in terms of trading volume for the day. Meanwhile, Novo Nordisk's shares fell due to concerns over its experimental obesity drug CagriSema, which showed less impressive results compared to Eli Lilly's Zepbound. Investors were also unimpressed with Amgen's weight-loss drug, which showed a 20% weight loss compared to Eli Lilly's Zepbound, which achieved up to 24%.

Eli Lilly's oral GLP-1 agonist Orforglipron, currently in Phase 3 trials, has shown promising results with statistically significant weight loss and improved HbA1c levels. This drug could further solidify Eli Lilly's position in the obesity market, which is projected to reach $10 billion by 2030. Amgen's experimental obesity drug, MariTide, is also making waves with its Phase 2 data showing superior weight loss and cardiometabolic benefits. MariTide's monthly dosing and tolerability could make it a strong competitor in the market. Eli Lilly's efsitora alfa insulin has also shown efficacy and safety in Phase 3 clinical trials, further strengthening its pipeline. However, Eli Lilly faces challenges as it plans to appeal a decision by the U.K.'s National Institute for Health and Care Excellence (NICE) to not endorse the use of its new drug. Despite these challenges, Eli Lilly's strong pipeline and market position make it a key player to watch in the pharmaceutical industry.